Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Share-based Compensation (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Share-based Compensation for 7 consecutive years, with $7.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 20.6% year-over-year to $7.3 million, compared with a TTM value of $28.7 million through Dec 2025, down 17.71%, and an annual FY2025 reading of $28.7 million, down 17.71% over the prior year.
  • Share-based Compensation was $7.3 million for Q4 2025 at Keros Therapeutics, up from $4.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $9.2 million in Q4 2024 and bottomed at $2.5 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $6.1 million, with a median of $6.4 million recorded in 2023.
  • The sharpest move saw Share-based Compensation surged 20683.33% in 2021, then crashed 54.79% in 2025.
  • Year by year, Share-based Compensation stood at $3.3 million in 2021, then skyrocketed by 44.04% to $4.7 million in 2022, then skyrocketed by 54.32% to $7.3 million in 2023, then rose by 25.61% to $9.2 million in 2024, then fell by 20.6% to $7.3 million in 2025.
  • Business Quant data shows Share-based Compensation for KROS at $7.3 million in Q4 2025, $4.0 million in Q3 2025, and $8.5 million in Q2 2025.